Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$248.68 USD
+1.07 (0.43%)
Updated Jul 3, 2024 01:00 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 281 - 300 ( 414 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Hemophilia Program Takes Shape, Bolstered by GalNac Delivery Platform
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Hemophilia Program Takes Shape, Bolstered by GalNac Delivery Platform
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming TTR-02 Data Should Provide Near-Term Catalyst to ALNY Shares
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pre-Clinical Data from ALNY Signals Growing Belief in siRNA Approaches Addressing Anemia
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pre-Clinical Data from ALNY Signals Growing Belief in siRNA Approaches Addressing Anemia
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Details from Phase II Trial of REGN727 and Plans for Phase III Released
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Details from Phase II Trial of REGN727 and Plans for Phase III Released
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Solid Quarter as Controls Costs and Sets Portfolio Priorities
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Solid Quarter as Controls Costs and Sets Portfolio Priorities
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M